Objective: The purpose of this study was to examine the association between diagnosed medical conditions and prospective crashes in commercial motor vehicle (CMV) drivers.
Methods: Three databases (demographics, medical conditions, and crashes) from the Saskatchewan Government Insurance (SGI) were linked and filtered to examine whether various medical diagnoses were associated with prospective crashes from 2007 to 2017. Univariate and cox proportional hazard analysis were calculated for medical conditions and their association with crash risk.
Results: Crashes occurred on average within 2 years following a medical diagnosis. Between 16% and 21% of drivers with diabetes, vision impairment, sleep apnea and cardiovascular disease crashed post diagnosis.
Conclusions: Licensing authorities and policy makers should consider further assessment if a CMV driver has been diagnosed with either diabetes or multiple sclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JOM.0000000000001914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glutamatergic Medications for Obsessive-Compulsive and Related Disorders: A Systematic Review and Meta-Analysis.
JAMA Netw Open
January 2025
Center for OCD and Related Disorders, Massachusetts General Hospital, Boston.
Importance: Obsessive-compulsive and related disorders (OCRDs) encompass various neuropsychiatric conditions that cause significant distress and impair daily functioning. Although standard treatments are often effective, approximately 60% of patients may not respond adequately, underscoring the need for novel therapeutic approaches.
Objective: To evaluate improvement in OCRD symptoms associated with glutamatergic medications as monotherapy or as augmentation to selective serotonin reuptake inhibitors, with a focus on double-blind, placebo-controlled randomized clinical trials (RCTs).
Esophagectomy Trends and Postoperative Outcomes at Private Equity-Acquired Health Centers.
JAMA Surg
January 2025
Department of Surgery, University of Michigan, Ann Arbor.
Importance: Growing trends in private equity acquisition of acute care hospitals in the US have motivated investigations into quality of care delivered at these health centers. While some studies have explored comparative outcomes for high-acuity medical conditions, care trends and outcomes of complex surgical procedures, such as esophagectomy, at private equity-acquired hospitals is unknown.
Objective: To compare structural characteristics and postoperative outcomes following esophagectomy between private equity-acquired and nonacquired health centers.
LINNAEUS: Simultaneous Single-Cell Lineage Tracing and Cell Type Identification.
Methods Mol Biol
January 2025
Charité Universitätsmedizin Berlin, Berlin, Germany.
A key goal of biology is to understand the origin of the many cell types that can be observed during diverse processes such as development, regeneration, and disease. Single-cell RNA-sequencing (scRNA-seq) is commonly used to identify cell types in a tissue or organ. However, organizing the resulting taxonomy of cell types into lineage trees to understand the origins of cell states and relationships between cells remains challenging.
View Article and Find Full Text PDFCKD-Associated Pruritus is Associated with Greater Use of Antidepressants and Anti-pruritus Medications.
Adv Ther
January 2025
CSL Vifor, Glattbrugg, Switzerland.
Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is a common, yet underdiagnosed condition among patients on hemodialysis. Considering the lack of established treatment pathways, we sought to evaluate the use of antidepressant, systemic antihistamines, or gabapentinoid medications among patients with CKD-aP in the year following pruritus assessment.
Methods: We included 6209 patients on hemodialysis in the analysis.
Diagnosis and treatment recommendations for glucose transporter 1 deficiency syndrome.
World J Pediatr
January 2025
The First Hospital of Peking University, Beijing, China.
Background: Glucose transporter 1 deficiency syndrome (Glut1DS) was initially reported by De Vivo and colleagues in 1991. This disease arises from mutations in the SLC2A1 and presents with a broad clinical spectrum. It is a treatable neuro-metabolic condition, where prompt diagnosis and initiation of ketogenic dietary therapy can markedly enhance the prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!